Joanna Gora-Tybor

Author PubWeight™ 6.84^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).	J Clin Oncol	2010	0.99
2	Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2).	Blood	2006	0.97
3	Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.	Blood	2007	0.91
4	Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.	Leuk Lymphoma	2007	0.82
5	Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.	Leuk Lymphoma	2004	0.81
6	Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.	Cancer	2009	0.80
7	Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukemia treated with cladribine.	Br J Haematol	2012	0.79
8	Elevated plasma levels of the angiogenic tetrapeptide acetyl-ser-asp-lys-pro are found in some patients with hematologic malignancies.	Leuk Lymphoma	2009	0.78
9	Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regiments or chlorambucil--follow-up of PALG-CLL randomized trials.	Eur J Haematol	2013	0.75
10	Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia.	Leuk Lymphoma	2013	0.75